Military Medical Academy
- Address
- Pushkin Str. 2, 8800 Sliven, Bulgaria
Bacterial Infections and Mycoses
The Military Medical Academy is conducting studies that target serious bacterial urinary infections, aiming to compare new oral antibiotics with traditional intravenous options.
- Complicated urinary tract infection (cUTI)
- Acute pyelonephritis (AP)
- Oral tebipenem versus IV imipenem‑cilastatin
- Microbiological eradication outcomes
These investigations help improve treatment pathways for patients with severe bacterial infections while monitoring antimicrobial resistance.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Research at the site includes foundational work on genetic and neonatal conditions, supporting future therapeutic advances even though current trials focus on metabolic and respiratory disorders.
- Genetic screening initiatives
- Neonatal health monitoring
- Collaboration with pediatric specialists
- Integration of hereditary disease registries
The academy’s expertise in hereditary medicine positions it to expand into targeted therapies for rare congenital disorders.
Nutritional and Metabolic Diseases
A key focus is severe hypertriglyceridemia, where investigators assess a novel lipid‑lowering agent for its ability to safely reduce triglyceride levels.
- Triglyceride reduction efficacy
- Safety and tolerability assessments
- Long‑term metabolic risk management
- Impact on cardiovascular risk markers
Outcomes from these studies aim to provide new options for patients at high risk of pancreatitis and cardiovascular events.
Respiratory Tract Diseases
The academy evaluates innovative treatments for asthma, particularly severe eosinophilic forms, to reduce exacerbations and improve quality of life.
- Uncontrolled moderate‑to‑severe asthma therapy
- Eosinophilic asthma management strategies
- Dexpramipexole long‑term safety
- Reduction in severe asthma attacks
These trials support the development of oral medications that may lessen reliance on high‑dose steroids.
Virus Diseases
Studies address influenza by monitoring antiviral resistance patterns and testing a next‑generation mRNA vaccine for broader protection.
- Baloxavir resistance surveillance
- mRNA‑1010 vaccine immunogenicity
- Effectiveness against influenza‑like illness
- Transmission dynamics in households
The goal is to enhance seasonal flu prevention and improve therapeutic options for viral infections.
Environment and Public Health
The site’s public‑health initiatives examine disease spread, vaccine impact, and environmental factors influencing infection rates.
- Household transmission studies
- Vaccination strategies for adults over 50
- Surveillance of viral mutation trends
- Assessment of environmental risk factors
By linking clinical findings with community health data, the academy contributes to broader public‑health preparedness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Military Medical Academy
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | Ionis Pharmaceuticals Inc. | Phase III | Not Recruiting | May 2023 | Sep 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 1 | Unknown | 2023-05-17 | 2023-05-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.